Shingles vaccination in Medicare Part D and commercial enrollees after the inflation reduction act

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-07-25 DOI:10.1016/j.vaccine.2025.127545

Emily Tang , Benjamin F. Arnold , Nisha R. Acharya

{"title":"Shingles vaccination in Medicare Part D and commercial enrollees after the inflation reduction act","authors":"Emily Tang , Benjamin F. Arnold , Nisha R. Acharya","doi":"10.1016/j.vaccine.2025.127545","DOIUrl":null,"url":null,"abstract":"<div><div>The impact of the 2022 United States Inflation Reduction Act policy on the recombinant zoster vaccine uptake in Medicare Part D enrollees remains unclear after cost-sharing was eliminated for vaccines recommended by the Advisory Committee on Immunization Practices. We implemented a difference-in-difference linear model with individuals aged 50 years and older from November 2021 to December 2024 from the Optum Labs Data Warehouse, a de-identified claims database, to compare the uptake in commercial and Medicare Part D enrollees following the policy change. Additionally, out-of-pocket costs were summarized.</div><div>Eliminating cost-sharing significantly increased recombinant zoster vaccine uptake among Medicare Part D beneficiaries. The estimated increase in vaccinations attributable to the policy change was 26.3 per 10,000 Medicare Part D enrollees (95 % CI: 11.2–41.4). The median out-of-pocket cost was $45.00 before and $0 after the policy change. Vaccine coverage remains insufficient, highlighting the need for targeted strategies to improve vaccination rates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127545"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25008424","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The impact of the 2022 United States Inflation Reduction Act policy on the recombinant zoster vaccine uptake in Medicare Part D enrollees remains unclear after cost-sharing was eliminated for vaccines recommended by the Advisory Committee on Immunization Practices. We implemented a difference-in-difference linear model with individuals aged 50 years and older from November 2021 to December 2024 from the Optum Labs Data Warehouse, a de-identified claims database, to compare the uptake in commercial and Medicare Part D enrollees following the policy change. Additionally, out-of-pocket costs were summarized.

Eliminating cost-sharing significantly increased recombinant zoster vaccine uptake among Medicare Part D beneficiaries. The estimated increase in vaccinations attributable to the policy change was 26.3 per 10,000 Medicare Part D enrollees (95 % CI: 11.2–41.4). The median out-of-pocket cost was $45.00 before and $0 after the policy change. Vaccine coverage remains insufficient, highlighting the need for targeted strategies to improve vaccination rates.

查看原文本刊更多论文

联邦医疗保险D部分的带状疱疹疫苗接种和通货膨胀减少法案后的商业参保者

在免疫实践咨询委员会推荐的疫苗取消了费用分摊后，2022年美国《减少通货膨胀法》政策对医疗保险D部分参保人接种重组带状疱疹疫苗的影响仍不清楚。我们从Optum实验室数据仓库（一个去识别的索赔数据库）中对2021年11月至2024年12月50岁及以上的个人实施了差异线性模型，以比较政策变化后商业和医疗保险D部分参保者的吸收情况。此外，还概述了自付费用。取消费用分摊显著增加了重组带状疱疹疫苗在医疗保险D部分受益人中的吸收。政策变化导致的疫苗接种估计增加为每10,000名医疗保险D部分参保者26.3人（95% CI: 11.2-41.4）。自付费用中位数在政策改变前为45美元，在政策改变后为0美元。疫苗覆盖率仍然不足，突出表明需要有针对性的战略来提高疫苗接种率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.